JP7637948B2 - Ｏ結合型ｎ－アセチルグルコサミン化タンパク質様物質及びこれを含有する線維症治療薬 - Google Patents

Ｏ結合型ｎ－アセチルグルコサミン化タンパク質様物質及びこれを含有する線維症治療薬 Download PDF

Info

Publication number
JP7637948B2
JP7637948B2 JP2021556161A JP2021556161A JP7637948B2 JP 7637948 B2 JP7637948 B2 JP 7637948B2 JP 2021556161 A JP2021556161 A JP 2021556161A JP 2021556161 A JP2021556161 A JP 2021556161A JP 7637948 B2 JP7637948 B2 JP 7637948B2
Authority
JP
Japan
Prior art keywords
linked
acetylglucosaminylated
protein
substance
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021556161A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021095828A1 (https=
JPWO2021095828A5 (https=
Inventor
裕彦 伊勢
早織 松尾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Somar Corp
Kyushu University NUC
Original Assignee
Somar Corp
Kyushu University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somar Corp, Kyushu University NUC filed Critical Somar Corp
Publication of JPWO2021095828A1 publication Critical patent/JPWO2021095828A1/ja
Publication of JPWO2021095828A5 publication Critical patent/JPWO2021095828A5/ja
Application granted granted Critical
Publication of JP7637948B2 publication Critical patent/JP7637948B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
    • C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F120/10—Esters
    • C08F120/34—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate
    • C08F120/36—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate containing oxygen in addition to the carboxy oxygen, e.g. 2-N-morpholinoethyl (meth)acrylate or 2-isocyanatoethyl (meth)acrylate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2021556161A 2019-11-14 2020-11-13 Ｏ結合型ｎ－アセチルグルコサミン化タンパク質様物質及びこれを含有する線維症治療薬 Active JP7637948B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019206265 2019-11-14
JP2019206265 2019-11-14
PCT/JP2020/042362 WO2021095828A1 (ja) 2019-11-14 2020-11-13 Ｏ結合型ｎ－アセチルグルコサミン化タンパク質様物質及びこれを含有する線維症治療薬

Publications (3)

Publication Number Publication Date
JPWO2021095828A1 JPWO2021095828A1 (https=) 2021-05-20
JPWO2021095828A5 JPWO2021095828A5 (https=) 2023-10-31
JP7637948B2 true JP7637948B2 (ja) 2025-03-03

Family

ID=75912746

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556161A Active JP7637948B2 (ja) 2019-11-14 2020-11-13 Ｏ結合型ｎ－アセチルグルコサミン化タンパク質様物質及びこれを含有する線維症治療薬

Country Status (7)

Country Link
US (1) US20220389047A1 (https=)
EP (1) EP4059567A4 (https=)
JP (1) JP7637948B2 (https=)
KR (1) KR102949437B1 (https=)
CN (1) CN114945609A (https=)
CA (1) CA3158028A1 (https=)
WO (1) WO2021095828A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250197865A1 (en) * 2022-03-03 2025-06-19 Kyushu University, National University Corporation Pharmaceutical composition for treatment or prevention of fibrotic disease
EP4603100A1 (en) * 2022-10-14 2025-08-20 Kyushu University, National University Corporation Antifibrotic agent, pharmaceutical composition for treating fibrosis, and method for inactivating myofibroblast
WO2025216313A1 (ja) * 2024-04-12 2025-10-16 国立大学法人九州大学 共重合体、抗線維化剤、線維症治療用医薬組成物及び筋線維芽細胞を不活性化する方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004526691A (ja) 2001-01-12 2004-09-02 エモリー　ユニバーシティ 糖ポリマーおよびフリーラジカル重合方法
WO2004099271A1 (ja) 2003-05-08 2004-11-18 Toyo Boseki Kabushiki Kaisha 糖鎖含有水溶性ポリマー化合物
JP2006276238A (ja) 2005-03-28 2006-10-12 Fuji Photo Film Co Ltd 光重合性組成物及び平版印刷版原版
US20140235790A1 (en) 2011-06-10 2014-08-21 University Of Washington Through Its Center For Commercialization Carbohydrate-based compositions and methods for targeted drug delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004043782A (ja) * 2002-05-09 2004-02-12 Toyobo Co Ltd オリゴ糖合成用水溶性高分子プライマー
JP2007518830A (ja) * 2003-12-31 2007-07-12 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ Ｎ−セチルグルコサミンを含有するオリゴマー
JP5044777B2 (ja) * 2006-05-09 2012-10-10 国立大学法人 東京医科歯科大学 細胞固定化基材被覆膜用材料
JP2011190257A (ja) 2010-02-22 2011-09-29 Oita Univ 組織線維化疾患の予防または治療剤
JP7109040B2 (ja) 2016-07-25 2022-07-29 国立大学法人金沢大学 線維化抑制剤
JP2019206265A (ja) 2018-05-29 2019-12-05 株式会社デンソー 車両用空調装置
JP7341031B2 (ja) * 2018-10-31 2023-09-08 ソマール株式会社 間葉系幹細胞の分離・選別方法、培養方法及びそれに用いる選別材料

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004526691A (ja) 2001-01-12 2004-09-02 エモリー　ユニバーシティ 糖ポリマーおよびフリーラジカル重合方法
WO2004099271A1 (ja) 2003-05-08 2004-11-18 Toyo Boseki Kabushiki Kaisha 糖鎖含有水溶性ポリマー化合物
JP2006276238A (ja) 2005-03-28 2006-10-12 Fuji Photo Film Co Ltd 光重合性組成物及び平版印刷版原版
US20140235790A1 (en) 2011-06-10 2014-08-21 University Of Washington Through Its Center For Commercialization Carbohydrate-based compositions and methods for targeted drug delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A. L.PARRY et al.，Glycopolymer-Functionalised Gold Nanoparticles : A New Strategy Towards Synthetic Anti-Cancer Vaccines，PMSE preprints，2009年，101，1331-1332，ISSN:0743-0515

Also Published As

Publication number Publication date
KR20220123383A (ko) 2022-09-06
TW202131933A (zh) 2021-09-01
JPWO2021095828A1 (https=) 2021-05-20
US20220389047A1 (en) 2022-12-08
CN114945609A (zh) 2022-08-26
KR102949437B1 (ko) 2026-04-08
EP4059567A1 (en) 2022-09-21
CA3158028A1 (en) 2021-05-20
WO2021095828A1 (ja) 2021-05-20
EP4059567A4 (en) 2023-11-22

Similar Documents

Publication Publication Date Title
JP7637948B2 (ja) Ｏ結合型ｎ－アセチルグルコサミン化タンパク質様物質及びこれを含有する線維症治療薬
US20090192085A1 (en) FKBP-L And Uses Thereof
UA126786C2 (uk) Fgfr/pd-1 комплексна терапія для лікування раку
US20090227489A1 (en) STAT3 Agonists and Antagonists and Therapeutic Uses Thereof
JP2017075184A (ja) アンチセンス組成物およびその作製および使用
JP4153564B2 (ja) 薬物性腎障害または薬物性肝障害の予防及び治療組成物
JP2025143437A (ja) ヒト対象者における心不全の治療
EP3804754A1 (en) Cmklr1 agonists having a resolvin e1-like capability and their therapeutic applications
WO2008095112A2 (en) Identification and use of agents that modulate oncogenic transcription agent activity
TWI917337B (zh) 氧連結型n-乙醯葡萄糖胺化類蛋白物質、及含有該氧連結型n-乙醯葡萄糖胺化類蛋白物質之纖維化症治療藥
CN111110666B (zh) 一种治疗消化道癌症的药物组合物
US20220220485A1 (en) PD-L1 antisense oligonucleotides for use in tumor treatment
TW202430194A (zh) 抗纖維化劑、纖維化症治療用醫藥組成物、及使肌纖維母細胞去活化的方法
AU2020425816A1 (en) Ligand-mediated delivery of therapeutic proteins and the uses thereof
CA2421723A1 (en) Stat3 agonists and antagonists and therapeutic uses thereof
WO2025216313A1 (ja) 共重合体、抗線維化剤、線維症治療用医薬組成物及び筋線維芽細胞を不活性化する方法
US20250163412A1 (en) Composition for prevention or treatment of liver cancer, comprising modified rt-let7 as active ingredient
JP2024058473A (ja) 筋線維芽細胞のα－平滑筋アクチン及びコラーゲンの発現抑制剤、線維症治療用医薬組成物、並びに、ｉｎ ｖｉｔｒｏで筋線維芽細胞のα－平滑筋アクチン及びコラーゲンの産生を抑制する方法
TW202608933A (zh) 共聚物、抗纖維化劑、用於治療纖維化症的醫藥組成物及不活化肌纖維母細胞的方法
WO2006046492A1 (ja) 新規ｐｐａｒ調節剤およびそのスクリーニング方法
WO2026055502A2 (en) Inhibin subunit beta e-related double stranded oligonucleotide compositions and methods relating thereto
WO2025169865A1 (ja) 変形性関節症及び／又は関節リウマチの予防及び／又は治療用医薬組成物
CN117255780A (zh) 脂联素糖肽和组合物以及其使用方法
PL213249B1 (pl) Zastosowanie pochodnych semikarbazydowych oraz 1,2,4-triazolino-5-onu posiadających układ 1-metylopirolu
Poosti et al. Targeted Renal Delivery of Protein Kinase Inhibitors for the Treatment of Chronic Kidney Disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250207

R150 Certificate of patent or registration of utility model

Ref document number: 7637948

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150